The PI3K/Akt pathway interacts with ERα and is often aberrantly upregulated in breast cancers, therefore a promising therapeutic strategy is to inhibit the molecular target of rapamycin (mTOR), a key downstream effector of the PI3K enzyme. This evidence concerns the gene AKT1 and breast cancer.